All In Biotech

Drug Trial Radar · NCT07931703

Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE)

A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Nov 12, 2026

Primary completion

Feb 13, 2028

Study completion Feb 13, 2028

Sponsor

Lead sponsor
Gedeon Richter Plc.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The reason for this trial is to see if the investigational product, called RGH-202, is safe and well tolerated, and can help people with social anxiety disorder. The main questions this study aims to answer are: * Is RGH-202 safe and well tolerated in adults with social anxiety disorder? * Does RGH-202 reduce symptoms of social anxiety disorder compared with placebo? RGH-202 will be compared with a placebo (a product that does not contain any active ingredients) to determine whether the investigational medicine may be an effective treatment for SAD. Participants will have an equal chance of receiving RGH-202 or the placebo taken for 6 weeks. Participants will attend regular clinic visits for safety assessments, study evaluations and complete questionnaires related to their social anxiety symptoms.

Conditions

  • Social Anxiety Disorder

Interventions

  • RGH-202Drug

    Oral capsule dosage form applied once daily for 42 days

  • PlaceboDrug

    Oral capsule dosage form applied once daily for 42 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: From enrollment to the end of follow-up at 8 week

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Leading Edge Research LA, LLC

    Encino, California

  • Clinical Neuroscience Solutions, LLC

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, LLC

    Orlando, Florida

  • Redbird Research LLC.

    Las Vegas, Nevada

  • Integrative Clinical Trials, LLC

    Brooklyn, New York

  • New Hope Clinical Research Inc.

    Charlotte, North Carolina

  • Clinical Neuroscience Solutions, LLC

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.